WILEX announces financial figures for the 2013 financial year and reports on course of business

PDF Download

Munich, 31 March 2014 – WILEX AG (ISIN DE0006614720 / WL6 / FSE) today published its financial results and annual report for the 2013 financial year (1 December 2012 – 30 November 2013). The WILEX Group generated sales revenue and other income totalling EUR 19.1 million (previous year: EUR 17.8 million). As a result of lower operating expenses totalling EUR 24.1 million (previous year: EUR 26.8 million) the net loss for the year was reduced significantly to EUR 5.0 million (previous year: EUR 9.4 million). Earnings per share improved from -EUR 0.36 in the previous year to -EUR 0.16.

The 2013 financial year nonetheless was not satisfactory for WILEX AG. Although the company can cite a number of operational areas where progress was made during the financial year, WILEX was unable to secure long-term financing or conclude a partnership deal for one of its product candidates. Accordingly, an extensive restructuring programme had to be introduced in January 2014, significantly changing the alignment and orientation of WILEX AG.

This restructuring programme calls for the stepwise discontinuation of clinical development and an 80% reduction in staff numbers at the company’s Munich premises. From mid-year, the WILEX Group will employ a total workforce of around 50 at two sites, and will concentrate its activities in the future on the preclinical service business of its subsidiary Heidelberg Pharma GmbH in Ladenburg as well as the further development and marketing of the innovative platform technology for therapeutic antibody drug conjugates (ADC technology). This strategy aims to significantly reduce current financing requirements while extending the cash reach for the remaining activities. WILEX AG will also be pushing ahead with the commercialisation of its clinical projects.

Dr Jan Schmidt-Brand, Chief Financial Officer of WILEX AG, commented: “Despite great efforts, we were unable to finance business operations in their previously existing form. In spite of many talks and negotiations with potential development and financing partners, we did not achieve our objective. We have been forced to realign WILEX and had no option but to bid farewell to many of our valued staff. From now on, we will be focusing on the further development and commercialisation of our innovative ADC technology, an area for which we have high hopes based on the findings to date and our ongoing partnerships.”

“We took an important step forward as regards the commercialisation of WILEX AG’s clinical portfolio.We are pleased to have agreed the first partnership for our uPA inhibitor MESUPRON® last Friday. Link Health will receive the exclusive licensing rights for the development and marketing of MESUPRON® in China, Hong Kong, Taiwan and Macao. While this deal will not materially affect our funds in the short term, the further development of this product candidate is an extremely important component of our strategy.”

Key events in the 2013 financial year

Status quo for clinical projects

Key events after the reporting period

Key financial figures of the WILEX Group for financial year 2013
The 2014 restructuring programme also had a massive impact on WILEX’s balance sheet as of 30 November 2013. As early as at the of the financial year, it had to be assumed that the Group would have been in danger of becoming insolvent in the third quarter of 2014 if business operations had continued as before without significant liquidity inflows from licensing or financing activities. Only the far-reaching restructuring programme initiated in late January (discontinuation of research and development activities and massive workforce reduction) enabled the cash reach to be extended and the financial statements to be prepared on a going-concern basis.

Against this backdrop, WILEX AG tested the recoverability of its assets and identified liabilities resulting discontinuing research and development activities at its Munich site. These tests resulted in the recognition of impairment losses on intangible assets, tangible assets and provisions for onerous contracts, which had a significant extraordinary negative impact on earnings both in terms of the consolidated financial statements (EUR 4.6 million) and the single-entity financial statements (EUR 6.0 million) of WILEX AG as of 30 November 2013.

Results of operations
WILEX posted sales revenue of EUR 13.3 million in the 2013 financial year, down 17% from the previous year (EUR 16.1 million). The sales revenue was generated primarily from the individual components of the licence agreement with Prometheus that was terminated in 2013.

At EUR 5.8 million, other income rose significantly compared to the previous year (EUR 1.7 million). It is significantly influenced by the sale of WILEX Inc. offsetting the disposal of net assets (EUR 0.2 million) against a consideration received (EUR 4.1 million) results in deconsolidation gain of EUR 3.9 million that is shown under other income. This item also includes grants from the Federal Ministry of Education and Research (BMBF) as well as income from the reversal of provisions and miscellaneous other income.

Operating expenses including depreciation and amortisation fell by 10% to EUR 24.1 million in 2013 (previous year: EUR 26.8 million). This decrease is attributable to the sale of WILEX Inc. in early September 2013 (consolidated expenses for just ten months), lower clinical development costs as well as other cost savings. At EUR 3.7 million, the costs of sales were 45% lower than in the previous year (EUR 6.7 million) and represent 15% of total costs. Research and development costs, which were EUR 12.8 million the previous year, fell by 3% to EUR 12.4 million, accounting for 52% of expenses. Administrative costs were EUR 4.2 million, down 14% on the prior-year level (EUR 4.9 million); the represent 18% of operating expenses. Other expenses amount to EUR 3.7 million (previous year: EUR 2.4 million), 57% higher than the prior-year figure and accounting for 15% of total costs.

The WILEX Group recognised considerably improved the operating result of -EUR 5.0 million (previous year: -EUR 8.9 million) in the 2013 financial year. The net loss for the year was also EUR 5.0 million (previous year: EUR 9.4 million). Earnings per share improved from -EUR 0.36 in the previous year to -EUR 0.16.

Total assets as of the close of the financial year were EUR 22.3 million, down substantially on the prior-year figure (EUR 37.7 million), which had been dominated by the capital measures and a payment from Prometheus. Non-current assets increased by 2% to EUR 12.8 million as of 30 November 2013 (previous year: EUR 12.5 million). Current assets decreased to EUR 9.5 million (previous year: EUR 25.2 million). WILEX had cash and cash equivalents of EUR 8.9 million (previous year: EUR 23.4 million) at the end of the reporting period. The monthly cash use decreased by 30% to EUR 1.2 million (previous year: EUR 1.7 million).

Non-current liabilities declined from EUR 1.1 million to EUR 0.1 million and current liabilities fell to EUR 7.3 million (previous year: EUR 16.7 million) at the end of the reporting period. Consolidated equity as of 30 November 2013 was EUR 14.9 million (previous year: EUR 19.9 million). This corresponds to an equity ratio of 67.0% (previous year: 52.8%).

The WILEX Group reported on three operating segments – Rx, Dx and Cx – which are explained in the segment reporting section in the management report of the 2013 annual report.

Financial outlook on 2014 of the WILEX Group
The WILEX Group is expected to generate between EUR 3.0 million and EUR 4.0 million in revenue and other income (2013: EUR 19.1 million) in the 2014 financial year. Based on current planning and following the successful implementation of the restructuring programme, operating expenses will be in the range of EUR 8.0 million to EUR 11.0 million, thus substantially below the previous year’s level (EUR 24.1 million). This requires the cost-cutting measures to be implemented as planned. Earnings before interest and taxes (EBIT) in the 2014 financial year are expected to be between -EUR 4.5 million and -EUR 7.5 million (2013: -EUR 5.0 million).

The results of operations in the next few years will depend to a large extent on whether additional master agreements for ADC partnerships and licence agreements can be concluded with several pharmaceutical partners in the area of customer-specific research and whether the service business can be expanded further. The planning does not include any income from the further commercialisation of the clinical projects.

If all measures are successfully implemented, the cash reach will be extended until the third quarter of 2015. WILEX anticipates a monthly cash use in 2014 of between EUR 0.3 million and EUR 0.5 million (2013: EUR 1.2 million).

Key figures for the WILEX Group

In EUR million

2013 1

EUR million

2012 1

EUR million




Sales revenue



Other income



Operating expenses



of which research and development costs



Operating result



Earnings before tax



Net loss for the year



Earnings per share in EUR






Balance sheet as of 30.11.2



Total assets



Cash and cash equivalents






Equity ratio in %3






Cash flow statement



Cash flow from operating activities



Cash flow from investing activities



Cash flow from financing activities






Employees (number)



Employees as of 30.11. 2, 4



 1 The reporting period begins on 1 December and ends on 30 November.
2 WILEX Inc. is no longer included in 2013.
3 Equity / total assets
4 Including members of the Executive Management Board

Rounding of exact figures may result in differences.

The annual report including the consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) was published at www.wilex.com.

Invitation to the conference call
On 31 March 2014, WILEX will hold a public conference call for media, analysts and investors in English at 3:00 p.m. CEST. Please dial in ten minutes before the conference call using the following dial-in numbers:

1. Germany: +49 69 71044 5598
2. UK: +44 20 3003 2666
3. USA: +1 212 999 6659
4. USA Freephone: +1 866 966 5335

You will be welcomed by an operator who will ask for the password (WILEX) and take your name and company. The presentation for the conference (in English) will be available for download from www.wilex.com at 2:30 p.m. CEST.

Corporate Communications
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 10, 81675 Munich
For press enquiries
MC Services AG
Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-126
Tel.: +49 (0)89-210 228-40
Mobile: +49 (0)160 9360 3022
Email: katja.arnold[at]mc-services.eu 


WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates based on antibodies and small molecules, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available at www.wilex.com

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Seite gelesen: 625 | Heute: 3